<--- Back to Details
First PageDocument Content
Health / Tuberculosis treatment / Multi-drug-resistant tuberculosis / Extensively drug-resistant tuberculosis / Latent tuberculosis / Rifampicin / Pyrazinamide / Isoniazid / Partners In Health / Tuberculosis / Medicine / Microbiology
Date: 2014-08-05 04:18:06
Health
Tuberculosis treatment
Multi-drug-resistant tuberculosis
Extensively drug-resistant tuberculosis
Latent tuberculosis
Rifampicin
Pyrazinamide
Isoniazid
Partners In Health
Tuberculosis
Medicine
Microbiology

ISTC Training Modules 2008 Drug-Resistant Tuberculosis Slide 1

Add to Reading List

Source URL: www.union-imdp.org

Download Document from Source Website

File Size: 2,69 MB

Share Document on Facebook

Similar Documents

For immediate release March 21, 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Moscow, Russia and Rockville, MD, USA -- Infecte

DocID: 1vkmw - View Document

TUBERCULOSIS AWARENESS WHAT IS TUBERCULOSIS? TB is an infectious disease which spreads through the air from person to person when droplet nuclei become airborne. These droplets are expelled from the lungs of a person wit

DocID: 1vhw7 - View Document

tuberculosis ●発行所/公益財団法人 結核予防会 結核研究所 対策支援部 結核対策推進会議新報 公益財団法人 結核予防会 結核研究所 2011年3月

DocID: 1vdV7 - View Document

C O N T R O L P R O G R A M tuberculosis

DocID: 1vc8r - View Document

Editorial Increasing the efficiency of detecting active tuberculosis cases in intermediate and high-burden tuberculosis countries: A way forward Tuberculosis (TB) is a major global health problem with an

DocID: 1vaaX - View Document